Welcome to Paradigm Therapeutics! Here at Paradigm, our mission is to improve the lives of patients experiencing serious, life-threatening diseases by the discovery, development and delivery of innovative therapies. Our lead therapy, Zorblesia™, is a proprietary topical therapy being developed for the treatment of patients with Epidermolysis Bullosa (EB).
Epidermolysis Bullosa (EB) is a rare genetic connective tissue disorder that typically manifests at birth or early childhood. Disease manifestations of EB include fragile skin that leads to blisters, wounds in the epidermis and dermis, poor wound healing, and skin infections that can be life-threatening. The therapeutic needs of these patients are underserved by the current treatment options available which only offer palliative care.
Zorblesia™ is a therapy that can be administered across the whole body of EB patients to address the disease manifestations of EB including wound healing, wound burden, and infections.
The 2026 USA finalists nominated for “Best Startup” have been announced. Paradigm Therapeutics has been selected as a finalist for the prestigious 2026 Prix Galien USA Award in the Start-Up category! Often called the “Nobel Prize of biopharmaceutical research,” this honor recognizes groundbreaking innovation in the life sciences. For us, this nomination highlights our unwavering […]
Please watch this video prepared ahead of Prix Galien gala:
The Post and Courier recently published a feature on Dr. Robert Ryan and the groundbreaking work happening at Paradigm Therapeutics. The article explores the journey behind SD-101, a topical therapy showing promise for patients with Epidermolysis Bullosa (EB), and the personal story that continues to drive the company’s mission forward.
First Topical Therapy Developed to Treat the Wounds and Lesions on the Entire Skin Surface Across All EB Subtypes Funding to be Used to Accelerate Activities Associated with Increasing Manufacturing Development of SD-101 and Commercial Launch of the SD-101 Program Globally. MT PLEASANT, S.C., June 18, 2025 /PRNewswire/ – Paradigm Therapeutics, Inc., a biopharmaceutical company, […]
First Topical Therapy Developed to Treat the Wounds and Lesions on the Entire Skin Surface Across All EB Subtypes Funding to be Used for Completion of All Activities to Support Planned NDA Submission in the Second Half of 2025, Along with Plans for Commercialization in the U.S. Mt Pleasant, S.C. (May 6, 2025) — Paradigm […]
‘Topical Therapy for Treating the Wounds and Lesions on the Entire Skin Surface’ MT PLEASANT, S.C., Aug. 22, 2023 — Paradigm Therapeutics Inc., a biopharmaceutical company, today announced the completion of the acquisition of the worldwide rights of SD-101, a topical whole-body treatment for all subtypes of Epidermolysis Bullosa (EB), from Amicus Therapeutics. Terms of the deal […]
Please tell us who you are so we can keep you updated on the future of treatments for EB.